HR 7651, the Chloe Cole Act of 2026, prohibits healthcare providers from performing certain medical interventions on minors under 18 aimed at altering physical development to align with gender identity. These "covered interventions" include puberty blockers, hormone treatments, and specific surgeries, but exclude medically necessary care for conditions like disorders of sexual development or traumatic injuries. The bill creates a federal civil lawsuit right for affected minors or their parents against providers who perform such interventions, allowing claims for damages including emotional distress and punitive awards, with strict liability for providers after the law's enactment. It explicitly allows exceptions for legitimate medical treatments and requires providers to prove such exceptions apply if challenged.
This bill requires Medicare Advantage plans to implement electronic pre-approval systems for medical services by 2028 and meet transparency reporting standards starting in 2027. Plans must publicly report data on approval/denial rates, appeal outcomes, response times, and technology use for pre-approval requests, including details on how denials relate to clinical criteria. It establishes a 24-hour response timeframe for certain requests and mandates annual reviews of pre-approval requirements based on data and input from seniors and providers. The law directly affects Medicare Advantage plans, seniors enrolled in these plans, and healthcare providers who submit pre-approval requests. These changes aim to make the pre-approval process faster, more transparent, and more accountable for seniors seeking covered medical services.
Protecting Privacy in Purchases Act This bill prohibits payment card networks from using merchant codes that distinguish firearms retailers from general-merchandise retailers or sporting-goods retailers. The Department of Justice must enforce this bill and report annually on the resulting investigations and cases.
The High Court Gift Ban Act prohibits federal judicial officers from accepting gifts from sources likely to appear before them, unless the gift is under $50, the total annual value from that source remains $100 or less, or it falls under specific exceptions like gifts from relatives or public events. The law defines a "gift" broadly to include items, services, and reimbursements, while allowing exceptions for personal hospitality within IRS limits and certain professional benefits available to the general public. Enforcement mechanisms include referrals to the Attorney General for violations, which can result in civil or criminal penalties similar to those for other federal ethics breaches. The bill requires the Supreme Court and the Judicial Conference to create implementing regulations within 180 days of enactment to ensure compliance.
The Fair Seeds for Farmers Act limits intellectual property protections for plants, specifically preventing patents from being granted on plant varieties, germplasm, or other biological materials used for breeding and research. Under this bill, farmers and researchers would be unable to face legal enforcement for contractual agreements that restrict their ability to save seeds, conduct experiments, or propagate plants, provided they are not using the Plant Variety Protection Act or the Plant Patent Act. The law applies to patent applications and contracts created on or after its enactment, while leaving existing patents valid if they were filed before the bill takes effect. This measure aims to ensure that plant-related research and traditional farming practices remain free from restrictive patent claims.
The REDACT Act amends the Epstein Files Transparency Act to allow private individuals to sue the federal government if their personal or medical information is improperly disclosed in released documents. Under this new provision, victims can file a civil lawsuit against the United States if an official fails to redact data that would constitute an unwarranted invasion of privacy. If a person wins the case, they could receive up to $50,000 for each violation, plus compensation for emotional distress and legal fees. The law applies to violations occurring on or after November 19, 2025, and gives plaintiffs five years from the date they learn of the breach to file a claim.
The Menopausal Workers' Fairness Act of 2026 expands federal employment protections to explicitly cover workers experiencing menopause and related symptoms, requiring employers with 15 or more employees to provide reasonable accommodations unless doing so causes significant business hardship. Under this bill, it would be illegal for employers to discriminate against or retaliate against qualified employees who request accommodations for issues such as hot flashes, fatigue, or mood changes, while also mandating that medical information regarding these conditions remains confidential. The legislation includes a specific list of low-cost adjustments, such as allowing extra restroom breaks or flexible sitting and standing, that employers must grant without requiring extensive documentation. Enforcement and legal remedies for violations will follow the same procedures currently used for age and disability discrimination claims, and the Equal Employment Opportunity Commission is tasked with issuing detailed regulations within a year of the law's passage.
This bill creates a five-year pilot program to provide grants to states and local governments for expanding Forensic Assertive Community Treatment teams. These specialized teams offer intensive, round-the-clock support including mental health care, addiction treatment, and housing assistance to individuals with serious mental illness who are involved with the criminal justice system. The program requires teams to include a mix of psychiatrists, employment specialists, criminal justice partners, and peer specialists with lived experience. Additionally, the legislation authorizes funding for a study by the National Academies to evaluate the program's effectiveness and develop guidelines for scaling it up.
The Expedited Access to Biosimilars Act modifies federal regulations to streamline the approval process for biosimilar drugs, which are lower-cost versions of existing biologic medicines. The bill requires manufacturers to conduct specific studies on how the drug behaves in the body and how the immune system reacts to it, while limiting the need for additional large-scale clinical trials unless the FDA explicitly determines they are necessary. To ensure transparency, the law mandates that the FDA must provide written notice to drug sponsors within 60 days regarding whether extra studies are required. These changes aim to reduce the time and cost involved in bringing biosimilars to market, potentially increasing patient access to affordable treatment options.
The American Enrichment Deployment Act modifies federal rules to allow the construction of uranium enrichment facilities to begin before a full operating license is granted. This change applies to companies building these facilities, permitting them to start construction under the same conditions used for other nuclear fuel cycle projects. The Nuclear Regulatory Commission must update its regulations within 180 days to implement these new procedures while retaining its authority to oversee safety and enforce compliance.
This joint resolution seeks to formally disapprove a specific rule issued by the Centers for Medicare & Medicaid Services regarding the Affordable Care Act and the Basic Health Program for 2027. If passed, the measure would nullify the rule, preventing it from taking legal effect. The bill directly impacts the administration of healthcare benefits and payment parameters for the upcoming year. It is sponsored by a group of Democratic senators and is intended to halt the implementation of the agency's proposed changes.
HR 5549, the Efficient Nuclear Licensing Hearings Act, streamlines the licensing process for nuclear facilities by reducing mandatory hearings. It allows the Nuclear Regulatory Commission (NRC) to issue construction permits, operating licenses, or amendments without a hearing if it provides 30 days' notice and Federal Register publication, skipping the hearing requirement only when an amendment involves "no significant hazards." This change applies to all pending NRC applications after enactment, shifting from current rules requiring hearings unless waived. The bill directly affects nuclear facility developers, the NRC, and communities potentially impacted by licensing decisions through its revised notice and hearing procedures.
